What Next for InMode Ltd. (INMD) Stock After Today’s Big Decline?

The stock of InMode Ltd. (NASDAQ:INMD) is a huge mover today! The stock decreased 9.66% or $2.58 during the last trading session, reaching $24.14. About 1.05 million shares traded. InMode Ltd. (NASDAQ:INMD) has 0.00% since September 8, 2018 and is . It has by 0.00% the S&P500.
The move comes after 7 months negative chart setup for the $574.84 million company. It was reported on Sep, 8 by Barchart.com. We have $23.42 PT which if reached, will make NASDAQ:INMD worth $17.25 million less.

InMode Ltd. (NASDAQ:INMD) Ratings Coverage

Among 4 analysts covering InMode (NASDAQ:INMD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. InMode has $3000 highest and $2700 lowest target. $28’s average target is 15.99% above currents $24.14 stock price. InMode had 4 analyst reports since September 3, 2019 according to SRatingsIntel.

More notable recent InMode Ltd. (NASDAQ:INMD) news were published by: Nasdaq.com which released: “Why InMode Shares Surged 12.9% Today – Nasdaq” on September 04, 2019, also Nasdaq.com with their article: “TRI Pointe Group Names Mike McMillen Vice President of Mergers and Acquisitions – Nasdaq” published on September 03, 2019, Finance.Yahoo.com published: “Paula Abdul Announced as InMode Brand Ambassador – Yahoo Finance” on August 13, 2019. More interesting news about InMode Ltd. (NASDAQ:INMD) were released by: Bizjournals.com and their article: “Union Bank and Trust completes rebranding, name change – Triad Business Journal” published on August 12, 2019 as well as Benzinga.com‘s news article titled: “InMode Opens Below IPO Price – Benzinga” with publication date: August 08, 2019.

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company has market cap of $574.84 million. The firm offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It has a 24.68 P/E ratio. It also designs, develops, makes, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.